Date: 2016-03-16
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Opko Health (USA - Fl)
Product: oxyntomodulin (MOD-6031)
Action
mechanism: peptide/glucagon receptor agonist. Oxyntomodulin is a peptide hormone that acts as a dual GLP-1/Glucagon receptor agonist, with the potential to promote weight loss while improving glycemic control. Oxyntomodulin has been shown to increase energy expenditure, while reducing food intake and body weight, although its clinical utility is limited by its short circulating half-life. MOD-6031 has been designed, using a proprietary bi-functional hydrolysable linker, as a long-acting version of oxyntomodulin for the treatment of Type II Diabetes and obesity, and is intended to reduce the required dosage frequency by prolonging the half-life, while improving the hormone's pharmacokinetics and pharmacodynamics.
Disease: obesity, type II diabetes
Therapeutic area: Metabolic diseases
Country: Israel
Trial details:
Latest
news: * On March 16, 2016, OPKO Health announced dosing of the first subject in a Phase 1 single dose escalation study evaluating the safety and pharmacokinetics of a long-acting oxyntomodulin (MOD-6031) in healthy, overweight or obese subjects. The study is intended to enroll 40 subjects in Israel.
